查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
疫苗合約製造市場：行業趨勢和2035年全球預測 - 按使用的表達系統類型、公司規模和地區
市場調查報告書
商品編碼
1534569

疫苗合約製造市場：行業趨勢和2035年全球預測 - 按使用的表達系統類型、公司規模和地區

Vaccine Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035: Type of Expression System Used, Company Size and Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 381 Pages | 商品交期: 最快1-2個工作天內

價格

到2024年，疫苗合約製造的市場規模預計為 23.8億美元，預計在2024-2035年預測期內年複合成長率為 6.5%。

隨著針對各種傳染病、腫瘤和自體免疫疾病的疫苗管道不斷增加，對疫苗合約生產的需求也在增加。合約製造商為製藥公司提供大規模製造服務，特別是 mRNA 和病毒載體等專用疫苗。疫苗在預防嚴重疾病方面發揮著重要作用，疫苗技術的最新進展代表著一個重要的里程碑。 FDA 批准的多種疫苗，包括首款針對呼吸道合胞病毒（RSV）和屈公病的疫苗，標誌著疫苗進入了新時代。

隨著疫苗需求的增加，專門從事疫苗的合約製造組織（CMO）的商機也在擴大。自2000年以來，已有130多家疫苗​​CMO成立，反映出合約製造商市場的不斷成長。為了保持競爭力，首席行銷長投資尖端工具和技術，並擴大其能力，以滿足日益成長的疫苗需求。

外包作為疫苗行業可行且有利的商業模式獲得認可，並推動全球疫苗合約製造市場的成長。此外，疫苗佐劑公司為疫苗開發商和製造商開發創新佐劑，這也推動了該市場的成長。

本報告檢視了全球疫苗合約製造市場，並提供了市場概況，包括按所使用的表達系統類型、公司規模和地區劃分的趨勢以及市場的未來前景。

目錄

第1章 前言

第2章 研究方法

第3章 經濟與其他專案特定考量

第4章 執行摘要

第5章 簡介

  • 章節概述
  • 依活性成分類型將疫苗分類
  • 疫苗配方的主要成分
  • 疫苗研發與生產
  • 疫苗的合約生產
  • 未來前景

第6章 市場狀況

  • 章節概述
  • 疫苗合約製造商：市場狀況

第7章 企業競爭力分析

  • 章節概述
  • 假設和主要參數
  • 調查方法
  • 企業競爭力分析：北美疫苗合約製造商
  • 公司競爭力分析：歐洲疫苗合約製造商
  • 企業競爭力分析：亞太地區疫苗合約製造商
  • 企業競爭力分析：其他地區的疫苗合約製造商

第8章 公司簡介：北美疫苗合約製造商

  • 章節概述
  • AGC Biologics
  • Bioreliance
  • Catalent
  • Charles River Laboratories
  • Curia
  • Meridian Life Science

第9章 公司簡介：歐洲疫苗合約製造商

  • 章節概述
  • Boehringer Ingelheim BioXcellence
  • Eurofins Amatsigroup
  • Eurogentec
  • IDT Biologika
  • Lonza

第10章 公司簡介：亞太疫苗合約製造商

  • 章節概述
  • Bharat Biotech
  • Biological E
  • GreenPak Biotech
  • Hong Kong Institute of Biotechnology
  • Syngene International
  • Wockhardt
  • WuXi Biologics

第11章 夥伴關係與協作

第12章 近期擴展

第13章 併購

第14章 能力分析

第15章 需求分析

第16章 供應商選擇框架分析

第17章 全球疫苗合約製造市場

  • 章節概述
  • 主要假設與研究方法
  • 全球疫苗合約製造市場，實績（2018-2023年）及預測（2024-2035年）
  • 主要市場細分
  • 全球 COVID-19 合約製造市場，實績（2018-2023年）和預測（2024-2035年）

第18章 全球疫苗合約生產市場（依使用的表達系統類型）

第19章 全球疫苗合約製造市場（依公司規模）

第20章 全球疫苗合約生產市場（依地區）

第21章 未來成長機會

  • 章節概述
  • 科技進步推動疫苗製造業的成長
  • 疫苗生產中向一次性系統和組件的過渡
  • 病毒樣顆粒（VLP）的出現
  • 增加對現有基礎設施的投資
  • 客戶/贊助商與 CMO/CDMO 之間不斷變化的關係
  • 業務收購與整合活動

第22章 SWOT分析

第23章 結論

第24章 高階主管見解

第25章 附錄 2：表格資料

第26章 附錄II公司與組織名單

Product Code: RA100506

The Vaccine Contract Manufacturing Market is valued at USD 2.38 billion in 2024 growing at a CAGR of 6.5% during the forecast period 2024-2035.

The demand for vaccine contract manufacturing is increasing, driven by the growing pipeline of vaccines targeting various infectious diseases, oncological and autoimmune disorders. Contract manufacturers provide large-scale production services to pharmaceutical companies, particularly for specialized vaccines like mRNA and viral vectors. Vaccines play a critical role in preventing serious illnesses, and recent advancements in vaccine technology have marked significant milestones. The approval of numerous FDA-approved vaccines, including the first vaccine for respiratory syncytial virus (RSV) and chikungunya, signals a shift towards a new era of vaccines.

As the demand for vaccines grows, opportunities for contract manufacturing organizations (CMOs) specializing in vaccines are expanding. Since 2000, over 130 vaccine CMOs have been established, reflecting the market expansion of contract service providers. To stay competitive, CMOs are investing in cutting-edge tools and technologies, expanding their capacities and capabilities to meet the escalating demand for vaccines.

Outsourcing is becoming increasingly accepted as a viable and beneficial business model in the vaccine industry, driving the growth of the global vaccine contract manufacturing market. Additionally, the success of vaccine adjuvants companies is also driven by the growth of this market, as they develop innovative adjuvants for vaccine developers and manufacturers.

Key Market Segments

Type of Expression System Used

  • Mammalian
  • Microbial
  • Others

Company Size

  • Small
  • Mid-sized
  • Large / Very Large

Key Geographical Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • A comprehensive overview of vaccine contract manufacturing is presented, focusing on the diverse expression systems utilized in the development and manufacturing of vaccines. Furthermore, the overview provides a brief description of the principles and advantages of contract manufacturing, highlighting its increasing importance in the vaccine industry.
  • A comprehensive analysis of the contract manufacturing landscape for vaccines is provided, including information on companies offering contract services, such as their year of establishment, company size, and location of headquarters. Additionally, this overview covers the types of services offered by these companies, including analytical testing, cell line development and virus banking, fill and finish, formulation development, process development, and regulatory consulting. The scale of operation is also examined, encompassing preclinical, clinical, and commercial stages. Furthermore, the overview explores the expression systems employed by these companies, including avian, insect, mammalian, microbial, and others. The review also delves into the types of vaccines manufactured by these companies, including live attenuated vaccines, inactivated vaccines, DNA vaccines, RNA-based vaccines (such as COVID-19 vaccines), subunit vaccines, toxoid-based vaccines, and others.
  • A comprehensive analysis of the competitiveness of key players in the contract vaccine manufacturing industry is presented, focusing on a multi-faceted evaluation of their company strengths. This assessment considers factors such as the experience and reputation of the contract manufacturer, as well as their portfolio strength, which encompasses various elements including the scale of their operation, the range of vaccines they manufacture, the types of services they offer, their manufacturing capabilities, and the number of facilities they operate.
  • Comprehensive profiles of the leading service providers in the vaccine contract manufacturing market, based in North America. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
  • An in-depth profiles of leading vaccine contract manufacturing service providers based in Europe are presented, providing a comprehensive overview of each company's strengths and capabilities. Each profile includes essential information such as the company's headquarters location, year of establishment, employee count, leadership team, service offerings, recent developments, and an expert forecast of future prospects. This detailed analysis enables a deeper understanding of the key players in the vaccine CMO market, their competitive positions, and their potential for growth and innovation.
  • Comprehensive profiles of the leading service providers in the vaccine contract manufacturing market, based in Asia-Pacific. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
  • A thorough examination of the partnerships forged between industry stakeholders in the vaccine contract manufacturing sector is presented, based on a range of criteria. This analysis delves into the details of partnerships signed between since 2019, including the year of partnership, partnership type, therapeutic area, type of vaccine manufactured, and type of partner. Additionally, the report highlights the most active players in the industry, as measured by the number of partnerships they have signed during this period. The regional distribution of partnership activity is also mapped, providing a comprehensive understanding of the trends and dynamics driving collaboration in the vaccine contract manufacturing industry.
  • A comprehensive examination of the expansion initiatives undertaken by vaccine contract manufacturers since 2020 is presented, analyzing various factors that influenced these developments. This analysis dissects the expansion initiatives based on key parameters, including the year of expansion, purpose of expansion (capacity expansion, capability expansion, new facility, geographical consolidation, and geographical expansion), location of the expanded facility, and investment amount. The report also identifies the most active players in the industry, measured by the number of expansion initiatives they have undertaken during this period. This in-depth analysis provides a detailed understanding of the strategic moves made by vaccine contract manufacturers to enhance their capabilities and expand their presence in the market.
  • A comprehensive examination of the mergers and acquisitions that have shaped the vaccine contract manufacturing industry since 2018 is presented, analyzing various factors that influenced these deals. This analysis delves into the details of mergers and acquisitions based on key parameters, including the year of agreement, type of deal (merger, acquisition, joint venture, etc.), geographical location of the companies involved, type of acquisition (asset, equity, etc.), type of biologic manufactured, therapeutic area, and key value drivers. The report provides a thorough understanding of the strategic moves made by companies in the industry to expand their capabilities, gain market share, and enhance their competitiveness. By examining these deals, this analysis aims to identify trends and patterns in the industry's M&A landscape.
  • A comprehensive estimate of the global vaccine manufacturing capacity is presented, based on publicly available data from industry stakeholders. The report highlights the distribution of available vaccine production capacity across various parameters, including company size (small, mid-sized, large, and very large firms), expression system used (mammalian, microbial, and others), and geographical region (North America, Europe, Asia-Pacific). This analysis provides a snapshot of the industry's current capacity landscape, enabling insights into the market share and competitive positioning of various vaccine manufacturers. By examining the distribution of capacity across different company sizes, expression systems, and regions, this report aims to shed light on the trends and patterns that shape the vaccine manufacturing industry.
  • An informed estimates of the annual commercial and clinical demand for vaccines, based on key geographical regions.
  • An insightful vendor selection framework analysis highlighting the parameters that should be considered while outsourcing operations to various vaccine manufacturing CMOs. The analysis was designed to enable stakeholder companies to evaluate a vendor for outsourcing their operations.
  • Comprehensive analysis capturing the key parameters and trends that are likely to influence the future of vaccine contract manufacturing, under a SWOT framework.
  • Comprehensive analysis of the factors that can impact the growth of vaccine contract manufacturing. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • Comprehensive estimate of the current market size and the future market growth potential of the vaccine contract manufacturing market over the next decade. Based on multiple parameters, such as likely adoption trends and through reliable secondary and primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within the vaccine contract manufacturing industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the market growth.
  • Comprehensive projections of the current and future opportunity for service providers in the vaccine CMO market across types of expression system used, namely mammalian, microbial and others.
  • Comprehensive projections of the current and future opportunity for service providers in the vaccine contract manufacturing market across company size, namely small, mid-sized and large / very large.
  • Detailed predictions of the current and future opportunity for service providers in the vaccine CMO market across different key geographical regions, namely North America, Europe, Asia-Pacific and rest of the world.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Vaccine Contract Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • AGC Biologics
  • Bharat Biotech
  • Biological E
  • BioReliance
  • Boehringer Ingelheim BioXcellence
  • Catalent
  • Charles River Laboratories
  • Cobra Biologics
  • Curia
  • Eurofins Amatsigroup
  • Eurogentec
  • GreenPak Biotech
  • Hong Kong Institute of Biotechnology
  • IDT Biologika
  • Lonza
  • Meridian Life Sciences
  • Syngene International
  • WuXi Biologics
  • Wockhardt

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databased and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

  • 4.1. Chapter Overview

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Classification of Vaccines based on Type of Active Ingredient
    • 5.2.1. Live, Attenuated Vaccines
    • 5.2.2. Inactivated Vaccines
    • 5.2.3. Subunit Vaccines
    • 5.2.4. Toxoid Vaccines
    • 5.2.5. DNA Vaccines
  • 5.3. Key Components of Vaccine Formulations
  • 5.4. Vaccine Development and Manufacturing
    • 5.4.1. Identification of Antigen and Manufacturing Process Development
    • 5.4.2. Production of Vaccines in Different Expression Systems
      • 5.4.2.1. Avian Expression Systems
      • 5.4.2.2. Bacterial Expression Systems
      • 5.4.2.3. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
      • 5.4.2.4. Insect Expression Systems
      • 5.4.2.5. Mammalian Expression Systems
      • 5.4.2.6. Plant Expression Systems
      • 5.4.2.7. Yeast Expression Systems
    • 5.4.3. Vaccine Manufacturing Process
      • 5.4.3.1. Upstream Process
      • 5.4.3.2. Downstream Process
      • 5.4.3.3. Formulation and Fill / Finish
    • 5.4.4. Clinical Development and Approval
    • 5.4.5. Vaccine Supply Chain and Logistics
  • 5.5. Vaccine Contract Manufacturing
    • 5.5.1. Need for Outsourcing Vaccine Manufacturing Operations
    • 5.5.2. Commonly Outsourced Operations
    • 5.5.3. Selecting a Contract Manufacturing Partner
    • 5.5.4. Advantages of Outsourcing Manufacturing Operations
    • 5.5.5. Risks and Challenges Associated with Contract Manufacturing
  • 5.6. Future Perspectives

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Vaccine Contract Manufacturers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by Type of Service Offered
    • 6.2.5. Analysis by Scale of Operation
    • 6.2.6. Analysis by Type of Expression System Used
    • 6.2.7. Analysis by Type of Vaccine Manufactured

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions And Key Parameters
  • 7.3. Methodology
  • 7.4. Company Competitiveness Analysis: Vaccine Contract Manufacturers in North America
  • 7.5. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Europe
  • 7.6. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Asia-Pacific
  • 7.7. Company Competitiveness Analysis: Vaccine Contract Manufacturers in Rest of the World

8. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN NORTH AMERICA

  • 8.1. Chapter Overview
  • 8.2. AGC Biologics
    • 8.2.1. Company Overview
    • 8.2.2. Recent Developments and Future Outlook
  • 8.3. Bioreliance
    • 8.3.1. Company Overview
    • 8.3.2. Recent Developments and Future Outlook
  • 8.4. Catalent
    • 8.4.1. Company Overview
    • 8.4.2. Recent Developments and Future Outlook
  • 8.5. Charles River Laboratories
    • 8.5.1. Company Overview
    • 8.5.2. Recent Developments and Future Outlook
  • 8.6. Curia
    • 8.6.1. Company Overview
    • 8.6.2. Recent Developments and Future Outlook
  • 8.7. Meridian Life Science
    • 8.7.1. Company Overview
    • 8.7.2. Recent Developments and Future Outlook

9. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN EUROPE

  • 9.1. Chapter Overview
  • 9.2. Boehringer Ingelheim BioXcellence
    • 9.2.1. Company Overview
    • 9.2.2. Recent Developments and Future Outlook
  • 9.3. Eurofins Amatsigroup
    • 9.3.1. Company Overview
    • 9.3.2. Recent Developments and Future Outlook
  • 9.4. Eurogentec
    • 9.4.1. Company Overview
    • 9.4.2. Recent Developments and Future Outlook
  • 9.5. IDT Biologika
    • 9.5.1. Company Overview
    • 9.5.2. Recent Developments and Future Outlook
  • 9.6. Lonza
    • 9.6.1. Company Overview
    • 9.6.2. Recent Developments and Future Outlook

10. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS IN ASIA-PACIFIC

  • 10.1. Chapter Overview
  • 10.2. Bharat Biotech
    • 10.2.1. Company Overview
    • 10.2.2. Recent Developments and Future Outlook
  • 10.3. Biological E
    • 10.3.1. Company Overview
    • 10.3.2. Recent Developments and Future Outlook
  • 10.4. GreenPak Biotech
    • 10.4.1. Company Overview
    • 10.4.2. Recent Developments and Future Outlook
  • 10.5. Hong Kong Institute of Biotechnology
    • 10.5.1. Company Overview
    • 10.5.2. Recent Developments and Future Outlook
  • 10.6. Syngene International
    • 10.6.1. Company Overview
    • 10.6.2. Recent Developments and Future Outlook
  • 10.7. Wockhardt
    • 10.7.1. Company Overview
    • 10.7.2. Recent Developments and Future Outlook
  • 10.8. WuXi Biologics
    • 10.8.1. Company Overview
    • 10.8.2. Recent Developments and Future Outlook

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Model
  • 11.3. Vaccine Contract Manufacturers: Partnerships and Collaborations
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Analysis by Year and Type of Partnership
    • 11.3.4. Analysis by Therapeutic Area
    • 11.3.5. Most Active Players: Analysis by Number of Partnerships
    • 11.3.6. Analysis by Geography
      • 11.3.6.1. Intracontinental and Intercontinental Agreements
      • 11.3.6.2. International and Local Deals

12. RECENT EXPANSIONS

  • 12.1. Chapter Overview
  • 12.2. Vaccine Contract Manufacturers: Recent Expansions
    • 12.2.1. Analysis by Year of Expansion
    • 12.2.2. Analysis by Purpose of Expansion
    • 12.2.3. Analysis by Year and Purpose of Expansion
    • 12.2.4. Analysis by Location of Expanded Facility
    • 12.2.5. Analysis by Purpose of Expansion and Location of Expanded Facility
    • 12.2.6. Analysis by Amount Invested
    • 12.2.7. Most Active Players: Analysis by Number of Recent Expansions

13. MERGERS AND ACQUSITIONS

  • 13.1. Chapter Overview
  • 13.2. Merger and Acquisition Models
  • 13.3. Vaccine Contract Manufacturing: Mergers and Acquisitions
    • 13.3.1. Analysis by Year of Agreement
    • 13.3.2. Analysis by Type of Agreement
    • 13.3.3. Analysis by Geography
      • 13.3.3.1. Intercontinental and Intracontinental Agreements
      • 13.3.3.2. Local and International Agreements
    • 13.3.4. Year-wise Trend in Key Geographies
    • 13.3.5. Most Active Players: Analysis by Number of Agreements
  • 13.4. Concluding Remarks

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Assumptions and Methodology
  • 14.3. Vaccine Contract Manufacturing: Global Installed Capacity
    • 14.3.1. Analysis by Company Size
    • 14.3.2. Analysis by Type of Expression System Used
    • 14.3.3. Analysis by Location of Manufacturing Facility
  • 14.4. Concluding Remarks

15. DEMAND ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Global Demand for Vaccines
    • 15.3.1. Global Clinical Demand for Vaccines
    • 15.3.2. Global Commercial Demand for Vaccines
  • 15.4. Analysis by Geography
  • 15.5. Global Clinical Demand for COVID-19 Vaccines
  • 15.6. Global Commercial Demand for COVID-19 Vaccines

16. VENDOR SELECTION FRAMEWORK ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Reasons to Outsource in Vaccine Manufacturing
  • 16.3. Commonly Outsourced Operations in Vaccine Manufacturing
  • 16.4. Key Parameters
  • 16.5. Methodology
  • 16.6. Comparison of Parameters
  • 16.7. Value Addition vs Evaluation Complexity Matrix
  • 16.8. Case Study Assessment of Leading Players
  • 16.9. Overview of Vendor Assessment Dashboard
    • 16.9.1. Scenario I
    • 16.9.2. Scenario II
    • 16.9.3. Scenario III
  • 16.10. Concluding Remarks

17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Global Vaccine Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.1. Scenario Analysis
      • 17.3.1.1. Conservative Scenario
      • 17.3.1.2. Optimistic Scenario
  • 17.4. Key Market Segmentation
  • 17.5. Global COVID-19 Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Vaccine Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2024 and 2035
    • 18.3.1. Vaccine Contract Manufacturing Market for Mammalian Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 18.3.2. Vaccine Contract Manufacturing Market for Microbial Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 18.3.3. Vaccine Contract Manufacturing Market for Other Expression Systems: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 18.4. Data Triangulation and Validation

19. VACCINE CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Vaccine Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
    • 19.3.1. Vaccine Contract Manufacturing Market for Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 19.3.2. Vaccine Contract Manufacturing Market for Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 19.3.3. Vaccine Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.4. Data Triangulation and Validation

20. VACCINE CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Vaccine Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
    • 20.3.1. Vaccine Contract Manufacturing Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.1. Vaccine Contract Manufacturing Market in US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.2. Vaccine Contract Manufacturing Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.3. Vaccine Contract Manufacturing Market in Rest of North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.4. Vaccine Contract Manufacturing Market for Mammalian Expression System in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.5. Vaccine Contract Manufacturing Market for Microbial Expression System in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.6. Vaccine Contract Manufacturing Market for Other Expression System t in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.7. Vaccine Contract Manufacturing Market for Small Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.8. Vaccine Contract Manufacturing Market for Mid-sized Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.1.9. Vaccine Contract Manufacturing Market for Large / Very Large Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.2. Vaccine Contract Manufacturing Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.1. Vaccine Contract Manufacturing Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.2. Vaccine Contract Manufacturing Market in UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.3. Vaccine Contract Manufacturing Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.4. Vaccine Contract Manufacturing Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.5. Vaccine Contract Manufacturing Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.6. Vaccine Contract Manufacturing Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.7. Vaccine Contract Manufacturing Market for Mammalian Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.8. Vaccine Contract Manufacturing Market for Microbial Expression System in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.9. Vaccine Contract Manufacturing Market for Other Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.10. Vaccine Contract Manufacturing Market for Small Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.11. Vaccine Contract Manufacturing Market for Mid-sized Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.2.12. Vaccine Contract Manufacturing Market for Large / Very Large Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.3. Vaccine Contract Manufacturing Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.1. Vaccine Contract Manufacturing Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.2. Vaccine Contract Manufacturing Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.3. Vaccine Contract Manufacturing Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.4. Vaccine Contract Manufacturing Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.5. Vaccine Contract Manufacturing Market for Mammalian Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.6. Vaccine Contract Manufacturing Market for Microbial Expression System in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.7. Vaccine Contract Manufacturing Market for Other Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.8. Vaccine Contract Manufacturing Market for Small Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.9. Vaccine Contract Manufacturing Market for Mid-sized Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
      • 20.3.3.10. Vaccine Contract Manufacturing Market for Large / Very Large Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
    • 20.3.4. Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 20.4. Data Triangulation and Validation

21. FUTURE GROWTH OPPORTUNITIES

  • 21.1. Chapter Overview
  • 21.2. Technological Advancements to Drive Growth in Vaccine Manufacturing Industry
  • 21.3. Shift to Single-Use Systems and Components for Vaccine Manufacturing
  • 21.4. The Advent of Virus-like Particles (VLPs)
  • 21.5. Growing Investments in Existing Infrastructure
  • 21.6. Evolving Client / Sponsor and CMO / CDMO Relationships
  • 21.7. Business Acquisition and Consolidation Activity

22. SWOT ANALYSIS

  • 22.1. Chapter Overview
  • 22.2. Strengths
  • 22.3. Weaknesses
  • 22.4. Opportunities
  • 22.5. Threats
  • 22.6. Comparison of SWOT Factors

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

  • 24.1. Chapter Overview
  • 24.2. Menzo Havenga, Chief Executive Officer and Claire Otjes, Marketing Manager, Batavia Biosciences
  • 24.3. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • 24.4. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • 24.5. Ingrid Kromann, Ex-Director of Vaccine Development, Statens Serum Institute
  • 24.6. Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
  • 24.7. Thilo Kamphausen, Director Business Development, Richer-Helm BioLogics
  • 24.8. Sebastian Schuck, Head of Business Development, Wacker Biotech
  • 24.9. Oliver Schub, Senior Business Development Manager, ProBioGen

25. APPENDIX 2: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 5.1 Classification of Vaccines based on their Type
  • Table 5.2 Toxoid Vaccines: Commonly Reported Adverse Events
  • Table 5.3 Vaccine Excipients and their Functions
  • Table 6.1 Vaccine Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters and Accreditations Received
  • Table 6.2 Vaccine Contract Manufacturers: Information on Type of Service Offered
  • Table 6.3 Vaccine Contract Manufacturers: Information on Scale of Operation
  • Table 6.4 Vaccine Contract Manufacturers: Information on Type of Expression System Used
  • Table 6.5 Vaccine Contract Manufacturers: Information on Type of Vaccine Manufactured
  • Table 8.1 Vaccine CMOs: List of Companies Profiled (North America)
  • Table 8.2 AGC Biologics: Company Overview
  • Table 8.3 AGC Biologics: Recent Development and Future Outlook
  • Table 8.4 Bioreliance: Company Overview
  • Table 8.5 Bioreliance: Recent Developments and Future Outlook
  • Table 8.6 Catalent: Company Overview
  • Table 8.7 Catalent: Recent Developments and Future Outlook
  • Table 8.8 Charles River Laboratories: Company Overview
  • Table 8.9 Charles River Laboratories: Recent Developments and Future Outlook
  • Table 8.10 Curia: Company Overview
  • Table 8.11 Curia: Recent Developments and Future Outlook
  • Table 8.12 Meridian Life Science: Company Overview
  • Table 8.13 Meridian Life Science: Recent Developments and Future Outlook
  • Table 9.1 Vaccine CMOs: List of Companies Profiled (Europe)
  • Table 9.2 Boehringer Ingelheim BioXcellence: Company Overview
  • Table 9.3 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
  • Table 9.4 Eurofins Amatsigroup: Company Overview
  • Table 9.5 Eurofins Amatsigroup: Recent Developments and Future Outlook
  • Table 9.6 Eurogentec: Company Overview
  • Table 9.7 Eurogentec: Recent Developments and Future Outlook
  • Table 9.8 IDT Biologika: Company Overview
  • Table 9.9 IDT Biologika: Recent Developments and Future Outlook
  • Table 9.10 Lonza: Company Overview
  • Table 9.11 Lonza: Recent Developments and Future Outlook
  • Table 10.1 Vaccine CMOs: List of Companies Profiled (Asia-Pacific)
  • Table 10.2 Bharat Biotech: Company Overview
  • Table 10.3 Bharat Biotech: Recent Developments and Future Outlook
  • Table 10.4 Biological E: Company Overview
  • Table 10.5 Biological E: Recent Developments and Future Outlook
  • Table 10.6 Hong Kong Institute of Biotechnology: Company Overview
  • Table 10.7 Hong Kong Institute of Biotechnology: Recent Developments and Future Outlook
  • Table 10.8 Syngene International: Company Overview
  • Table 10.9 Syngene International: Recent Developments and Future Outlook
  • Table 10.10 Wockhardt: Company Overview
  • Table 10.11 Wockhardt: Recent Developments and Future Outlook
  • Table 10.12 WuXi Biologics: Company Overview
  • Table 10.13 WuXi Biologics: Recent Developments and Future Outlook
  • Table 11.1 Vaccine Contract Manufacturers: List of Partnerships and Collaborations, 2020-2024
  • Table 12.1 Vaccine Contract Manufacturers: List of Recent Expansions, 2020-2024
  • Table 13.1 Vaccine Contract Manufacturers: List of Mergers and Acquisitions, 2015-2024
  • Table 14.1 Capacity Analysis: Average Capacity for Mammalian Expression System
  • Table 14.2 Capacity Analysis: Average Capacity for Microbial Expression System
  • Table 14.3 Capacity Analysis: Installed Global Capacity
  • Table 26.1 Vaccine Contract Manufacturers: Distribution by Year of Establishment
  • Table 26.2 Vaccine Contract Manufacturers: Distribution by Company Size
  • Table 26.3 Vaccine Contract Manufacturers: Distribution by Location of Headquarters (Region)
  • Table 26.4 Vaccine Contract Manufacturers: Distribution by Location of Headquarters (Country)
  • Table 26.5 Vaccine Contract Manufacturers: Distribution by Type of Service Offered
  • Table 26.6 Vaccine Contract Manufacturers: Distribution by Scale of Operation
  • Table 26.7 Vaccine Contract Manufacturers: Distribution by Type of Expression System Used
  • Table 26.8 Vaccine Contract Manufacturers: Distribution by Type of Vaccine Manufactured
  • Table 26.9 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2020-2024
  • Table 26.10 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 26.11 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 26.12 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 26.13 Most Active Players: Distribution by Number of Partnerships
  • Table 26.14 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 26.15 Partnerships and Collaborations: Local and International Agreements
  • Table 26.16 Recent Expansions: Cumulative Year-wise Trend, 2020-2023
  • Table 26.17 Recent Expansions: Distribution by Type of Expansion
  • Table 26.18 Recent Expansions: Distribution by Year and Type of Expansion
  • Table 26.19 Recent Expansions: Distribution by Location of Expanded Facility
  • Table 26.20 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
  • Table 26.21 Recent Expansions: Distribution by Amount Invested (USD Million)
  • Table 26.22 Most Active Players: Distribution by Number of Expansions
  • Table 26.23 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2024
  • Table 26.24 Mergers and Acquisitions: Distribution by Type of Acquisition
  • Table 26.25 Mergers and Acquisitions: Local and International Agreements
  • Table 26.26 Mergers and Acquisitions: Intercontinental and Intracontinental Agreements
  • Table 26.27 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015-2024)
  • Table 26.28 Most Active Players: Distribution by Number of Deals
  • Table 26.29 Capacity Analysis: Distribution by Company Size
  • Table 26.30 Capacity Analysis: Distribution by Type of Expression System Used
  • Table 26.31 Capacity Analysis: Distribution by Location of Manufacturing Facility
  • Table 26.32 Global Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
  • Table 26.33 Global Clinical Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
  • Table 26.34 Global Commercial Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
  • Table 26.35 Global Commercial Demand for Vaccines Historical Trends (2020-2023) and Forecasted Estimates (2024-2035): Distribution by Geographical Region (in Million Doses)
  • Table 26.36 Global Clinical Demand for COVID-19 Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035)
  • Table 26.37 Global Commercial Demand for COVID-19 Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035)
  • Table 26.38 Global Vaccine Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.39 Global Vaccine Contract Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
  • Table 26.40 Global Vaccine Contract Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
  • Table 26.41 Vaccine Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2024 and 2035
  • Table 26.42 Vaccine Contract Manufacturing Market for Mammalian Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.43 Vaccine Contract Manufacturing Market for Microbial Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.44 Vaccine Contract Manufacturing Market for Other Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.45 Vaccine Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
  • Table 26.46 Vaccine Contract Manufacturing Market for Small Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • Table 26.47 Vaccine Contract Manufacturing Market for Mid-sized Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • Table 26.48 Vaccine Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • Table 26.49 Vaccine Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • Table 26.50 Vaccine Contract Manufacturing Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.51 Vaccine Contract Manufacturing Market in US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.52 Vaccine Contract Manufacturing Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.53 Vaccine Contract Manufacturing Market in Rest of North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.54 Vaccine Contract Manufacturing Market for Mammalian Expression System in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.55 Vaccine Contract Manufacturing Market for Microbial Expression System in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.56 Vaccine Contract Manufacturing Market for Other Expression System t in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.57 Vaccine Contract Manufacturing Market for Small Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.58 Vaccine Contract Manufacturing Market for Mid-sized Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.59 Vaccine Contract Manufacturing Market for Large / Very Large Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.60 Vaccine Contract Manufacturing Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.61 Vaccine Contract Manufacturing Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.62 Vaccine Contract Manufacturing Market in UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.63 Vaccine Contract Manufacturing Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.64 Vaccine Contract Manufacturing Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.65 Vaccine Contract Manufacturing Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.66 Vaccine Contract Manufacturing Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.67 Vaccine Contract Manufacturing Market for Mammalian Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.68 Vaccine Contract Manufacturing Market for Microbial Expression System in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.69 Vaccine Contract Manufacturing Market for Other Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.70 Vaccine Contract Manufacturing Market for Small Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.71 Vaccine Contract Manufacturing Market for Mid-sized Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.72 Vaccine Contract Manufacturing Market for Large / Very Large Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.73 Vaccine Contract Manufacturing Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.74 Vaccine Contract Manufacturing Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.75 Vaccine Contract Manufacturing Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.76 Vaccine Contract Manufacturing Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.77 Vaccine Contract Manufacturing Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.78 Vaccine Contract Manufacturing Market for Mammalian Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.79 Vaccine Contract Manufacturing Market for Microbial Expression System in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.80 Vaccine Contract Manufacturing Market for Other Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.81 Vaccine Contract Manufacturing Market for Small Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.82 Vaccine Contract Manufacturing Market for Mid-sized Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.83 Vaccine Contract Manufacturing Market for Large / Very Large Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.84 Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Table 26.85 Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)

List of Figures

  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentations
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Vaccine Contract Manufacturers Market Landscape
  • Figure 4.2 Executive Summary: Partnerships and Collaborations
  • Figure 4.3 Executive Summary: Recent Expansions
  • Figure 4.4 Executive Summary: Mergers and Acquisitions
  • Figure 4.5 Executive Summary: Capacity Analysis
  • Figure 4.6 Executive Summary: Demand Analysis
  • Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 5.1 Classification of Vaccines
  • Figure 5.2 Vaccine Manufacturing Process
  • Figure 5.3 Key Steps in Vaccine Transportation Process
  • Figure 5.4 Types of Third-Party Service Providers in the Pharmaceutical Industry
  • Figure 5.5 Risks and Challenges Associated with Contract Manufacturing
  • Figure 6.1 Vaccine Contract Manufacturers: Distribution by Year of Establishment
  • Figure 6.2 Vaccine Contract Manufacturers: Distribution by Company Size
  • Figure 6.3 Vaccine Contract Manufacturers: Distribution by Location of Headquarters (Region)
  • Figure 6.4 Vaccine Contract Manufacturers: Distribution by Location of Headquarters (Country)
  • Figure 6.5 Vaccine Contract Manufacturers: Distribution by Type of Service Offered
  • Figure 6.6 Vaccine Contract Manufacturers: Distribution by Scale of Operation
  • Figure 6.7 Vaccine Contract Manufacturers: Distribution by Type of Expression System Used
  • Figure 6.8 Vaccine Contract Manufacturers: Distribution by Type of Vaccine Manufactured
  • Figure 7.1 Company Competitiveness Analysis: Very Large Vaccine Contract Manufacturers based in North America
  • Figure 7.2 Company Competitiveness Analysis: Large Vaccine Contract Manufacturers based in North America
  • Figure 7.3 Company Competitiveness Analysis: Mid-Sized Vaccine Contract Manufacturers based in North America
  • Figure 7.4 Company Competitiveness Analysis: Small and Very Small Vaccine Contract Manufacturers based in North America
  • Figure 7.5 Company Competitiveness Analysis: Very Large Vaccine Contract Manufacturers based in Europe
  • Figure 7.6 Company Competitiveness Analysis: Large Vaccine Contract Manufacturers based in Europe
  • Figure 7.7 Company Competitiveness Analysis: Mid-Sized Vaccine Contract Manufacturers based in Europe
  • Figure 7.8 Company Competitiveness Analysis: Small and Vey Small Vaccine Contract Manufacturers based in Europe
  • Figure 7.9 Company Competitiveness Analysis: Very Large Vaccine Contract Manufacturers based in Asia-Pacific
  • Figure 7.10 Company Competitiveness Analysis: Large Vaccine Contract Manufacturers based in Asia-Pacific
  • Figure 7.11 Company Competitiveness Analysis: Mid-Sized Vaccine Contract Manufacturers based in Asia-Pacific
  • Figure 7.12 Company Competitiveness Analysis: Small and Very Small Vaccine Contract Manufacturers based in Asia-Pacific
  • Figure 7.13 Company Competitiveness Analysis: Vaccine Contract Manufacturers based in Rest of the World
  • Figure 11.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2020-2024
  • Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 11.4 Partnerships and Collaborations: Distribution by Therapeutic Area

Figure11.5 Most Active Players: Distribution by Number of Partnerships

  • Figure 11.6 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 11.7 Partnerships and Collaboration: Local and International Agreements
  • Figure 12.1 Recent Expansions: Cumulative Year-wise Trend, 2020-2023
  • Figure 12.2 Recent Expansions: Distribution by Type of Expansion
  • Figure 12.3 Recent Expansions: Distribution by Year and Purpose of Expansion
  • Figure 12.4 Recent Expansions: Distribution by Location of Expanded Facility
  • Figure 12.5 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
  • Figure 12.6 Recent Expansions: Distribution by Amount Invested (USD Million)
  • Figure 12.7 Most Active Players: Distribution by Number of Expansions
  • Figure 13.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2024
  • Figure 13.2 Mergers and Acquisitions: Distribution by Type of Acquisition
  • Figure 13.3 Mergers and Acquisitions: Local and International Agreements
  • Figure 13.4 Mergers and Acquisitions: Intercontinental and Intracontinental Agreements
  • Figure 13.5 Most Active Acquirers: Distribution by Number of Acquisitions
  • Figure 13.6 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015-2024)
  • Figure 14.1 Capacity Analysis: Distribution by Company Size
  • Figure 14.2 Capacity Analysis: Distribution by Type of Expression System Used
  • Figure 14.3 Capacity Analysis: Distribution by Location of Manufacturing Facility
  • Figure 15.1 Global Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
  • Figure 15.2 Global Clinical Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
  • Figure 15.3 Global Commercial Demand for Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035) (in Million Doses)
  • Figure 15.4 Global Commercial Demand for Vaccines Historical Trends (2020-2023) and Forecasted Estimates (2024-2035): Distribution by Geographical Region (in Million Doses)
  • Figure 15.5 Global Clinical Demand for COVID-19 Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035)
  • Figure 15.6 Global Commercial Demand for COVID-19 Vaccines, Historical Trends (2020-2023) and Forecasted Estimates (2024-2035)
  • Figure 16.1 Vendor Selection Framework: Comparison of Parameters
  • Figure 17.1 Vaccine Contract Manufacturing: Market Drivers
  • Figure 17.2 Vaccine Contract Manufacturing: Market Restraints
  • Figure 17.3 Vaccine Contract Manufacturing: Market Opportunities
  • Figure 17.4 Vaccine Contract Manufacturing: Market Challenges
  • Figure 18.1 Global Vaccine Contract Manufacturing Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.2 Global Vaccine Contract Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
  • Figure 18.3 Global Vaccine Contract Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
  • Figure 19.1 Vaccine Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2024 and 2035
  • Figure 19.2 Vaccine Contract Manufacturing Market for Mammalian Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.3 Vaccine Contract Manufacturing Market for Microbial Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.4 Vaccine Contract Manufacturing Market for Other Expression System: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 20.1 Vaccine Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
  • Figure 20.2 Vaccine Contract Manufacturing Market for Small Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • Figure 20.3 Vaccine Contract Manufacturing Market for Mid-sized Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • Figure 20.4 Vaccine Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • Figure 21.1 Vaccine Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • Figure 21.2 Vaccine Contract Manufacturing Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.3 Vaccine Contract Manufacturing Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.4 Vaccine Contract Manufacturing Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.5 Vaccine Contract Manufacturing Market in Rest of North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.6 Vaccine Contract Manufacturing Market for Mammalian Expression System in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.7 Vaccine Contract Manufacturing Market for Microbial Expression System in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.8 Vaccine Contract Manufacturing Market for Other Expression System in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.9 Vaccine Contract Manufacturing Market for Small Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.10 Vaccine Contract Manufacturing Market for Mid-sized Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.11 Vaccine Contract Manufacturing Market for Large / Very Large Companies in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.12 Vaccine Contract Manufacturing Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.13 Vaccine Contract Manufacturing Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.14 Vaccine Contract Manufacturing Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.15 Vaccine Contract Manufacturing Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.16 Vaccine Contract Manufacturing Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.17 Vaccine Contract Manufacturing Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.18 Vaccine Contract Manufacturing Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.19 Vaccine Contract Manufacturing Market for Mammalian Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.20 Vaccine Contract Manufacturing Market for Microbial Expression System in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.21 Vaccine Contract Manufacturing Market for Other Expression System in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.22 Vaccine Contract Manufacturing Market for Small Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.23 Vaccine Contract Manufacturing Market for Mid-sized Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.24 Vaccine Contract Manufacturing Market for Large / Very Large Companies in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.25 Vaccine Contract Manufacturing Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.26 Vaccine Contract Manufacturing Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.27 Vaccine Contract Manufacturing Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.28 Vaccine Contract Manufacturing Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.29 Vaccine Contract Manufacturing Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.30 Vaccine Contract Manufacturing Market for Mammalian Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.31 Vaccine Contract Manufacturing Market for Microbial Expression System in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.32 Vaccine Contract Manufacturing Market for Other Expression System in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.33 Vaccine Contract Manufacturing Market for Small Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.34 Vaccine Contract Manufacturing Market for Mid-sized Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.35 Vaccine Contract Manufacturing Market for Large / Very Large Companies in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.36 Vaccine Contract Manufacturing Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 23.1 Vaccine Contract Manufacturing: SWOT Analysis
  • Figure 24.1 Concluding Remarks: Vaccine Contract Manufacturers Market Landscape
  • Figure 24.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 24.3 Concluding Remarks: Recent Expansions
  • Figure 24.4 Concluding Remarks: Mergers and Acquisitions
  • Figure 24.5 Concluding Remarks: Capacity Analysis
  • Figure 24.6 Concluding Remarks: Demand Analysis
  • Figure 24.7 Concluding Remarks: Market Forecast and Opportunity Analysis